Page 3 - Acarix News Today

Press release Malmö, December 29, 2021 Acarix carries out a directed issue of shares to guarantors in conjunction with completed rights issue Acarix AB ("Acarix" or the "Company") has, as previously

Acarix publishes prospectus in connection with rights issue of approximately SEK 79 million The Extraordinary General Meeting of Acarix AB ("Acarix" or the "Company") resolved on 23 November 2021

Press release Malmö, November 23, 2021 Announcement from Acarix's extra general meeting The extra general meeting of Acarix AB ("Acarix" or the "Company") was held today on 23 November 2021

Press release (MAR) Malmö, Sweden, November 5, 2021 Acarix decides on a fully guaranteed rights issue of approximately SEK 79,3 million to expand on the US market INSIDE INFORMATION: The Board

Notice of Extra General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the extra general meeting to be held on Tuesday 23 November

Press release (MAR)Malmö, Sweden, October 27, 2021 Acarix granted US CPT reimbursement code for CADScor System The editorial panel of the American Medical Association (AMA) today approved the Category

Press releaseMalmö, Sweden, August 27, 2021 Initial Dan-NICAD II results presented today at ESC Study confirms excellent rule-out capacity of CADScor, almost 50% of intermediate

Press release Malmö, August 19, 2021 Acarix AB (publ) publishes Interim Report, January - June 2021 Continued positive trend with focus on US expansion The second quarter continued

Notice of Annual General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the " Company"), are hereby convened to the annual general meeting to be held on Tuesday 11 May 2021. Information with respect to the coronavirus The Company is mindful of the health and well-being of its shareholders and employees. Its important for the Company to take a social responsibility and contribute to reduce the risk of transmission of the coronavirus (Covid-19). Due to the extraordinar...

Acarix AB: A strong ending of an eventful year A strong ending of an eventful year The fourth quarter contributed strongly to our overall performance in 2020, with the market approval for CADScor from the US Food and Drug Administration (FDA) as the outstanding achievement. Extract from CEO Per Perssons message to the End Year Report. Fourth quarter 2020 compared with same period 2019 During the fourth quarter, 22 CADScorSystem (10, of which 4 to clinical trials) and 1,420 (1,500, of which 840 ...